Clinical Trial Update: Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating adding nivolumab to standard therapy for patients with metastatic or unresectable colorectal cancer with a BRAF mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Colorectal Cancer
• Rectal Cancer
• Unresectable Colorectal Cancer

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING